Femara and Tumor marker increased - a phase IV clinical study of FDA data
Tumor marker increased is found among people who take Femara, especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months.
The phase IV clinical study analyzes which people take Femara and have Tumor marker increased. It is created by eHealthMe based on reports of 17,170 people who have side effects when taking Femara from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
17,170 people reported to have side effects when taking Femara.
Among them, 222 people (1.29%) have Tumor marker increased.
What is Femara?
Femara has active ingredients of letrozole. It is often used in breast cancer. eHealthMe is studying from 17,692 Femara users for its effectiveness, alternative drugs and more.
What is Tumor marker increased?
Tumor marker increased is found to be associated with 588 drugs and 309 conditions by eHealthMe.
Number of Femara and Tumor marker increased reports submitted per year:
Time on Femara when people have Tumor marker increased *:
Gender of people who have Tumor marker increased when taking Femara*:
Age of people who have Tumor marker increased when taking Femara *:
Common drugs people take besides Femara *:
Common side effects people have besides Tumor marker increased *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Femara and have Tumor marker increased?Check whether Tumor marker increased is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Tumor marker increased and when was it recovered:
Expand to all the drugs that have ingredients of letrozole:
Alternative drugs to, pros and cons of Femara:
- Femara (17,692 reports)
Common Femara side effects:
Browse all side effects of Femara:a b c d e f g h i j k l m n o p q r s t u v w x y z
Tumor marker increased treatments and more:
- Tumor marker increased (4,193 reports)
COVID vaccines that are related to Tumor marker increased:
- Tumor marker increased in Moderna COVID Vaccine
- Tumor marker increased in Pfizer BioNTech Covid Vaccine
- Tumor marker increased in Johnson and Johnson Covid Vaccine
Common drugs associated with Tumor marker increased:
All the drugs that are associated with Tumor marker increased:
- Tumor marker increased (588 drugs)
Common conditions associated with Tumor marker increased:
- Breast cancer: 488 reports
- Breast cancer female: 160 reports
- Breast cancer metastatic: 522 reports
- Cancer - breast: 518 reports
- Cancer - ovaries: 500 reports
- High blood pressure: 111 reports
- Metastases to bone: 131 reports
- Ovarian cancer: 440 reports
All the conditions that are associated with Tumor marker increased:
- Tumor marker increased (309 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on letrozole (the active ingredients of Femara) and Femara (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Ultram Er and Presyncope - 5 seconds ago
- Exjade and Encephalopathy - 11 seconds ago
- Vyepti and Celecoxib drug interaction - 12 seconds ago
- Bumetanide and Stable Angina - 13 seconds ago
- Cyclophosphamide and Red Blood Cells Urine Positive - 14 seconds ago
- Verapamil Hcl and Pulmonary Mass - 14 seconds ago
- Atovaquone and Motrin drug interaction - 15 seconds ago
- Celexa and Disseminated Intravascular Coagulation - 16 seconds ago
- Tacrolimus and Bladder Cancer Recurrent - 19 seconds ago
- Dabigatran Etexilate and Hypoglycemia - 19 seconds ago